Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in Asian subjects with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials

Jun Yong Choi, Somnuek Sungkanuparph, Thanomsak Anekthananon, Paul Sax, Edwin DeJesus, Howard Edelstein, Mark Nelson, Jennifer DeMorin, Hui C. Liu, Raji Swamy, Joonwoo Bahn, Sun Jin Hwang, Sang Youn Yang, Christopher Ng, David Piontkowsky

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) were analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-na�ve and ART-experienced Asian subjects infected with human immunodeficiency virus (HIV)-1. Studies GS-US-236-102 and GS-US-236-103 were randomized, double-blind, placebo-controlled, 144-week studies conducted in ART-na�ve subjects, comparing E/C/F/TDF versus efavirenz (EFV)/F/TDF or ritonavir-boosted atazanavir (ATV+RTV) plus emtricitabine/tenofovir DF (F/TDF), respectively. Studies GS-US-236-115 and GS-US-236-121 were randomized, open-label, 96-week long conducted in ART-experienced subjects, who switched to E/C/F/TDF from ritonavir-boosted protease inhibitors (PI+RTV)+F/TDF, or non-nucleoside reverse transcriptase inhibitors (NNRTI)+F/TDF regimens. The E/C/F/TDF appeared to have sustained efficacy and safety and was well tolerated in the small number of ART-na�ve and ART-experienced Asian subjects.

Original languageEnglish
Pages (from-to)219-224
Number of pages6
JournalInfection and Chemotherapy
Volume48
Issue number3
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Phase III Clinical Trials
Virus Diseases
HIV-1
Safety
Ritonavir
Tenofovir
efavirenz
Therapeutics
Reverse Transcriptase Inhibitors
Protease Inhibitors
Tablets
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Placebos

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Choi, Jun Yong ; Sungkanuparph, Somnuek ; Anekthananon, Thanomsak ; Sax, Paul ; DeJesus, Edwin ; Edelstein, Howard ; Nelson, Mark ; DeMorin, Jennifer ; Liu, Hui C. ; Swamy, Raji ; Bahn, Joonwoo ; Hwang, Sun Jin ; Yang, Sang Youn ; Ng, Christopher ; Piontkowsky, David. / Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in Asian subjects with human immunodeficiency virus 1 infection : A sub-analysis of phase 3 clinical trials. In: Infection and Chemotherapy. 2016 ; Vol. 48, No. 3. pp. 219-224.
@article{509382ac309447d79bb49b791564517a,
title = "Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in Asian subjects with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials",
abstract = "The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) were analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-na{\"i}¿½ve and ART-experienced Asian subjects infected with human immunodeficiency virus (HIV)-1. Studies GS-US-236-102 and GS-US-236-103 were randomized, double-blind, placebo-controlled, 144-week studies conducted in ART-na{\"i}¿½ve subjects, comparing E/C/F/TDF versus efavirenz (EFV)/F/TDF or ritonavir-boosted atazanavir (ATV+RTV) plus emtricitabine/tenofovir DF (F/TDF), respectively. Studies GS-US-236-115 and GS-US-236-121 were randomized, open-label, 96-week long conducted in ART-experienced subjects, who switched to E/C/F/TDF from ritonavir-boosted protease inhibitors (PI+RTV)+F/TDF, or non-nucleoside reverse transcriptase inhibitors (NNRTI)+F/TDF regimens. The E/C/F/TDF appeared to have sustained efficacy and safety and was well tolerated in the small number of ART-na{\"i}¿½ve and ART-experienced Asian subjects.",
author = "Choi, {Jun Yong} and Somnuek Sungkanuparph and Thanomsak Anekthananon and Paul Sax and Edwin DeJesus and Howard Edelstein and Mark Nelson and Jennifer DeMorin and Liu, {Hui C.} and Raji Swamy and Joonwoo Bahn and Hwang, {Sun Jin} and Yang, {Sang Youn} and Christopher Ng and David Piontkowsky",
year = "2016",
month = "1",
day = "1",
doi = "10.3947/ic.2016.48.3.219",
language = "English",
volume = "48",
pages = "219--224",
journal = "Infection and Chemotherapy",
issn = "2093-2340",
publisher = "Taehan Kamyom Hakhoe, Taehan Hwahak Yopop Hakhoe",
number = "3",

}

Choi, JY, Sungkanuparph, S, Anekthananon, T, Sax, P, DeJesus, E, Edelstein, H, Nelson, M, DeMorin, J, Liu, HC, Swamy, R, Bahn, J, Hwang, SJ, Yang, SY, Ng, C & Piontkowsky, D 2016, 'Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in Asian subjects with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials', Infection and Chemotherapy, vol. 48, no. 3, pp. 219-224. https://doi.org/10.3947/ic.2016.48.3.219

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in Asian subjects with human immunodeficiency virus 1 infection : A sub-analysis of phase 3 clinical trials. / Choi, Jun Yong; Sungkanuparph, Somnuek; Anekthananon, Thanomsak; Sax, Paul; DeJesus, Edwin; Edelstein, Howard; Nelson, Mark; DeMorin, Jennifer; Liu, Hui C.; Swamy, Raji; Bahn, Joonwoo; Hwang, Sun Jin; Yang, Sang Youn; Ng, Christopher; Piontkowsky, David.

In: Infection and Chemotherapy, Vol. 48, No. 3, 01.01.2016, p. 219-224.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in Asian subjects with human immunodeficiency virus 1 infection

T2 - A sub-analysis of phase 3 clinical trials

AU - Choi, Jun Yong

AU - Sungkanuparph, Somnuek

AU - Anekthananon, Thanomsak

AU - Sax, Paul

AU - DeJesus, Edwin

AU - Edelstein, Howard

AU - Nelson, Mark

AU - DeMorin, Jennifer

AU - Liu, Hui C.

AU - Swamy, Raji

AU - Bahn, Joonwoo

AU - Hwang, Sun Jin

AU - Yang, Sang Youn

AU - Ng, Christopher

AU - Piontkowsky, David

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) were analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-na�ve and ART-experienced Asian subjects infected with human immunodeficiency virus (HIV)-1. Studies GS-US-236-102 and GS-US-236-103 were randomized, double-blind, placebo-controlled, 144-week studies conducted in ART-na�ve subjects, comparing E/C/F/TDF versus efavirenz (EFV)/F/TDF or ritonavir-boosted atazanavir (ATV+RTV) plus emtricitabine/tenofovir DF (F/TDF), respectively. Studies GS-US-236-115 and GS-US-236-121 were randomized, open-label, 96-week long conducted in ART-experienced subjects, who switched to E/C/F/TDF from ritonavir-boosted protease inhibitors (PI+RTV)+F/TDF, or non-nucleoside reverse transcriptase inhibitors (NNRTI)+F/TDF regimens. The E/C/F/TDF appeared to have sustained efficacy and safety and was well tolerated in the small number of ART-na�ve and ART-experienced Asian subjects.

AB - The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) were analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-na�ve and ART-experienced Asian subjects infected with human immunodeficiency virus (HIV)-1. Studies GS-US-236-102 and GS-US-236-103 were randomized, double-blind, placebo-controlled, 144-week studies conducted in ART-na�ve subjects, comparing E/C/F/TDF versus efavirenz (EFV)/F/TDF or ritonavir-boosted atazanavir (ATV+RTV) plus emtricitabine/tenofovir DF (F/TDF), respectively. Studies GS-US-236-115 and GS-US-236-121 were randomized, open-label, 96-week long conducted in ART-experienced subjects, who switched to E/C/F/TDF from ritonavir-boosted protease inhibitors (PI+RTV)+F/TDF, or non-nucleoside reverse transcriptase inhibitors (NNRTI)+F/TDF regimens. The E/C/F/TDF appeared to have sustained efficacy and safety and was well tolerated in the small number of ART-na�ve and ART-experienced Asian subjects.

UR - http://www.scopus.com/inward/record.url?scp=84992190569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992190569&partnerID=8YFLogxK

U2 - 10.3947/ic.2016.48.3.219

DO - 10.3947/ic.2016.48.3.219

M3 - Article

AN - SCOPUS:84992190569

VL - 48

SP - 219

EP - 224

JO - Infection and Chemotherapy

JF - Infection and Chemotherapy

SN - 2093-2340

IS - 3

ER -